BioSpace News Archive

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Thursday, February 27, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the fourth quarter and full year 2019 and provide a corporate update.

Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (OTCQB:TBPMF) today announced the initiation of its clinical trial for its synthetic cannabinoid therapy (PPP003v) for the treatment of ophthalmic eye pain in the veterinary setting.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced results from the monotherapy and combination arms of the Company’s ongoing Phase 1/2 study investigating ADXS-503 in patients with non-small cell lung cancer (NSCLC) at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting in Santa Monica, California.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report fourth quarter 2019 financial results on Thursday, February 27, 2020, after the close of U.S. markets.

WINNIPEG, Manitoba, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and

HABRI and Mars Petcare partnership reveals roadmap for future research, best practices and solutions to increase impact of companion animals on social isolation and loneliness

- Dr. Lonberg Brings an Extensive Background in Immunology and Oncology as Bolt Initiates Phase I Studies in Cancer Patients and Builds Pipeline - REDWOOD CITY, Calif. , Feb. 20, 2020 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harnes

The health system is the first in the world to combine the advanced cerebrovascular imaging software, RapidAI, and Pulsara’s secure mobile communication platform to improve stroke treatment processes

Feb. 20, 2020 13:00 UTC Eureka Therapeutics to Present at 6 th Annual Immuno-Oncology 360° Conference EMERYVILLE, Calif.--( BUSINESS WIRE )-- Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that President and CEO Dr. Cheng Liu will be presenting at the 6 th Annual Immuno-Oncology 360° Conference (IO360°) in New York on February 27, 2020. Dr. Liu will be presenting the use of Eureka’s n

Feb. 20, 2020 13:00 UTC Lineage Cell Therapeutics to Present at Biocom’s 10 th Annual Global Life Sciences Partnering Conference CARLSBAD, Calif.--( BUSINESS WIRE )-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at Biocom’s 10 th Annual Global Life Sciences Partnering Conference o